136 related articles for article (PubMed ID: 18549624)
1. [Effects of thalidomide on CD4(+)CD25(+) T regulatory cells in patients with multiple myeloma].
Yang Y; Zhang WG; He AL; Yang HY; Wang JL; Tian W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):538-42. PubMed ID: 18549624
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.
Herth I; Witzens-Harig M; Beckhove P; Hose D; Meissner T; Neuber B; Engelhardt M; Haas J; Neben K; Ho AD; Klein B; Goldschmidt H; Hundemer M
Exp Hematol; 2013 Mar; 41(3):231-40. PubMed ID: 23142220
[TBL] [Abstract][Full Text] [Related]
3. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
Raja KR; Plasil M; Rihova L; Pelcova J; Adam Z; Hajek R
Cytometry B Clin Cytom; 2014 Jul; 86(4):220-8. PubMed ID: 23922218
[TBL] [Abstract][Full Text] [Related]
5. Role of new population of peripheral CD11c(+)CD8(+) T cells and CD4(+)CD25(+) regulatory T cells during acute and remission stages in rheumatoid arthritis patients.
Kao JK; Hsue YT; Lin CY
J Microbiol Immunol Infect; 2007 Oct; 40(5):419-27. PubMed ID: 17932602
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome.
Alunno A; Petrillo MG; Nocentini G; Bistoni O; Bartoloni E; Caterbi S; Bianchini R; Baldini C; Nicoletti I; Riccardi C; Gerli R
Rheumatology (Oxford); 2013 Aug; 52(8):1387-96. PubMed ID: 23674818
[TBL] [Abstract][Full Text] [Related]
7. Low circulating CD4(+) CD25(+) Foxp3(+) T regulatory cell levels predict miscarriage risk in newly pregnant women with a history of failure.
Winger EE; Reed JL
Am J Reprod Immunol; 2011 Oct; 66(4):320-8. PubMed ID: 21314851
[TBL] [Abstract][Full Text] [Related]
8. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.
Muthu Raja KR; Rihova L; Zahradova L; Klincova M; Penka M; Hajek R
PLoS One; 2012; 7(10):e47077. PubMed ID: 23071717
[TBL] [Abstract][Full Text] [Related]
9. Foxp3(high) and Foxp3(low) Treg cells differentially correlate with T helper 1 and natural killer cells in peripheral blood.
Lee SK; Kim JY; Jang BW; Hur SE; Na BJ; Lee M; Fukui A; Gilman-Sachs A; Kwak-Kim J
Hum Immunol; 2011 Aug; 72(8):621-6. PubMed ID: 21600259
[TBL] [Abstract][Full Text] [Related]
10. [Change of CD4(+) CD25(+) regulatory T cells and NK Cells in peripheral blood of children with acute leukemia and its possible significance in tumor immunity].
Wu ZL; Hu GY; Chen FX; Lu HM; Wu ZL; Li HM; Wei FG; Guan JM; Wu LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):709-13. PubMed ID: 20561434
[TBL] [Abstract][Full Text] [Related]
11. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden.
Feyler S; von Lilienfeld-Toal M; Jarmin S; Marles L; Rawstron A; Ashcroft AJ; Owen RG; Selby PJ; Cook G
Br J Haematol; 2009 Mar; 144(5):686-95. PubMed ID: 19133978
[TBL] [Abstract][Full Text] [Related]
12. Micro-inflammation characterized by disturbed Treg/Teff balance with increasing sIL-2R in patients with type 2 diabetes.
Cai B; Zhang J; Zhang M; Li L; Feng W; An Z; Wang L
Exp Clin Endocrinol Diabetes; 2013 Apr; 121(4):214-9. PubMed ID: 23595796
[TBL] [Abstract][Full Text] [Related]
13. The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.
Strupp C; Germing U; Aivado M; Kündgen A; Fenk R; Hünerlitürkoglu A; Kobbe G; Haas R; Gattermann N
Leuk Lymphoma; 2005 Jul; 46(7):999-1006. PubMed ID: 16019550
[TBL] [Abstract][Full Text] [Related]
14. [The subpopulation CD4(+); CD25(+); Foxp3(+);/CD127(low/-); regulatory T cells in peripheral blood of HIV-infected patients correlated with disease progression].
Chen YL; Chen XR; Qin LX; Yang YF; Tang YM
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov; 28(11):1188-91. PubMed ID: 23127412
[TBL] [Abstract][Full Text] [Related]
15. Analysis of peripheral blood T-cell subsets and regulatory T-cells in multiple myeloma patients.
Huang LQ; Wang JX; He K; Jiang YZ; Wei ZL; Huang DP; Chu LL
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):113-117. PubMed ID: 29729703
[TBL] [Abstract][Full Text] [Related]
16. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer.
He Q; Li G; Ji X; Ma L; Wang X; Li Y; Fan C
Tumour Biol; 2017 May; 39(5):1010428317697571. PubMed ID: 28475005
[TBL] [Abstract][Full Text] [Related]
17. CD4(+) and CD8(+) regulatory T cells in chronic rhinosinusitis mucosa.
Pant H; Hughes A; Schembri M; Miljkovic D; Krumbiegel D
Am J Rhinol Allergy; 2014; 28(2):e83-9. PubMed ID: 24717938
[TBL] [Abstract][Full Text] [Related]
18. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis.
Ferri S; Longhi MS; De Molo C; Lalanne C; Muratori P; Granito A; Hussain MJ; Ma Y; Lenzi M; Mieli-Vergani G; Bianchi FB; Vergani D; Muratori L
Hepatology; 2010 Sep; 52(3):999-1007. PubMed ID: 20683931
[TBL] [Abstract][Full Text] [Related]
19. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
[TBL] [Abstract][Full Text] [Related]
20. TLR2 agonists enhance CD8+Foxp3+ regulatory T cells and suppress Th2 immune responses during allergen immunotherapy.
Tsai YG; Yang KD; Niu DM; Chien JW; Lin CY
J Immunol; 2010 Jun; 184(12):7229-37. PubMed ID: 20483759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
